Clinical Trial Update: Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluated intravesical epirubicin plus BCG for preventing recurrence in patients with transitional cell carcinoma of the bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Bladder

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) intravesical vaccine (Bacillus Calmette-Guérin)
• Epirubicin (epirubicin)

Snippet

Sponsor: LanZhou University | Conditions: Bladder Neoplasms | Phase 2 | Status: COMPLETED